Procter & Gamble Health Ltd

Procter & Gamble Health Ltd has announced a revised date for its 59th Annual General Meeting (AGM), now scheduled for Thursday, September 3, 2026. The record date for the purpose of the AGM and the potential payment of a final dividend has been set for Thursday, August 27, 2026. If approved by members at the AGM, the dividend is expected to be paid to eligible shareholders by September 27, 2026. This update supersedes previous communications regarding the AGM schedule.

Procter & Gamble Health Ltd announced its Board of Directors has recommended a final dividend of ₹45 per equity share for the financial year 2025-26. This dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM). The company also detailed the Tax Deducted at Source (TDS) implications for dividend income, outlining applicable rates for resident and non-resident shareholders. Resident shareholders with PAN will face a 10% TDS if their total dividend exceeds ₹10,000, while those without a valid PAN will be subject to 20% TDS. Specific exemptions and documentation requirements are provided for entities like LIC, GIC, Mutual Funds, and government bodies. Non-resident shareholders will be taxed at 20% or the Double Taxation Avoidance Agreement (DTAA) rate, whichever is lower.

Procter & Gamble Health Ltd has announced the closure of its trading window for directors and designated employees. The window will be effective from July 1, 2026, and will remain closed until 48 hours after the publication of the company's unaudited financial results for the quarter ended June 30, 2026. This measure is a standard corporate governance practice to prevent insider trading during sensitive financial reporting periods.

Procter & Gamble Health Ltd has announced that its Board of Directors will convene on August 6, 2026. The primary agenda item for this meeting is to consider and approve the unaudited financial results for the first quarter ended June 30, 2026. This announcement is made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Procter & Gamble Health Ltd has announced significant changes in its Senior Management Personnel, effective July 1, 2026. These internal organizational shifts involve key roles within the sales and marketing functions. Mr. Abhijit Roy will transition to Sales Leader (South and East region) and Exports Leader. Mr. M. Padmakar Rao will become Sales Leader (North & West region) and Institutional Business Leader. Mr. Nilesh Barbade is appointed as Sales Leader (Trade). Mr. Shine Matthew Sunny will join as Marketing Strategy and Planning leader, Commercial Excellence & E-commerce Leader. The company has confirmed that these individuals will continue to be part of the Senior Management team.

Procter & Gamble Health Ltd has announced that the record date for the purpose of the 59th Annual General Meeting and payment of dividend, if approved by the members, will be August 21, 2026. The 59th Annual General Meeting of the Company is scheduled to be held on August 27, 2026.

Procter & Gamble Health Ltd's board has recommended a final dividend of ₹45 per equity share (Nominal Value of ₹10/- each) for the financial year ended March 31, 2026, subject to shareholder approval. The dividend is to be paid on or before September 25, 2026. The board also approved the audited financial results for FY26, reporting revenue from operations of ₹140797 lakhs and a net profit of ₹32691 lakhs.

Procter & Gamble Health Ltd has re-appointed Mr. S. Madhavan as an Independent Director for a term of five years, effective from November 15, 2026, subject to shareholder approval. Mr. Madhavan meets the criteria for independence as per the Companies Act, 2013 and SEBI regulations. He does not hold any shares in the company and is not disqualified from holding office.

Procter & Gamble Health Ltd announced its financial results for the fourth quarter and fiscal year ended March 31, 2026. Sales for the quarter stood at ₹365 crores, up 20% YoY, while Profit After Tax (PAT) was ₹95 crores, up 55% YoY. The company reported sales of ₹1385 crores and PAT of ₹327 crores for the 12-month financial year, up 16% and 30% respectively, compared to the comparable 12-month period last year. The Board recommended a final dividend of ₹45 per share, bringing the total dividend payout for the fiscal to ₹205 per share.

Procter & Gamble Health Ltd's audited financial results for the year ended March 31, 2026, were approved in a board meeting held on May 26, 2026. The company reported revenue from operations of ₹1407.97 Cr and a net profit of ₹326.91 Cr for the financial year ended March 31, 2026. The Board recommended a dividend of ₹45 per equity share (Nominal Value of ₹10 each), to be paid on or before September 25, 2026, subject to member approval.